Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Effect of Antiulcer Drugs on Helicobacter pylori

  • 4 Accesses

  • 4 Citations


Helicobacter pylori is an important pathogen. It causes type B gastritis and is a probable pathogenic factor in duodenal ulcer disease. In vitro, H. pylori is susceptible to a large number of antimicrobial agents as well as to a few antiulcer agents, including bismuth salts [colloidal tripotassium dicitrato bismuthate (TDB), bismuth salicylate and bismuth subnitrate], metronidazole, furazolidone and sofalcone. In vivo efficacy of monotherapy in eradicating H. pylori long term is poor, with the best agent being colloidal TDB. In uncontrolled studies, polytherapy incorporating TDB is most effective, with eradication rates of over 90%.

The identification of a safe, effective regimen to eradicate H. pylori requires a detailed understanding of mucosal and systemic actions of the agents together with well conducted, controlled clinical trials.

This is a preview of subscription content, log in to check access.


  1. Berstad A, Alexander B, Weberg R. Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with non ulcer dyspepsia and erosive prepyloric changes. Gastroenterology 95: 619–624, 1988

  2. Bayordorffer E, Simon T, Bastlein C. Bismuth/ofloxacin combination for duodenal ulcer. Lancet 2: 1467–1468, 1987

  3. Borody TJ, Cole P, Noonan S, Morgan A. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Medical Journal of Australia 151: 431–435, 1989

  4. Börsch G, Mai U, Müller KM. Monotherapy or polychemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease. Scandinavian Journal of Gastroenterology 23(Suppl. 142): 101–106, 1988

  5. Glupczynski Y, Labbe M, Burette A, Delmee M, Avesani V, et al. Treatment failure of ofloxacin in Camplyobacter pylori infection. Lancet 1: 1096, 1987

  6. Goodwin CS, Armstrong JA, Chilvers T, Peters M, Collins MD, et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gon. nov. as Helicobacter pylori comb, nov. and Helicobacter mustelae comb. nov. respectively. International Journal of Systematic Bacteriology 39: 397–405, 1989

  7. Goodwin CS, Blake P, Blincow G. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents, against Campylobacter pyloridis. Journal of Antimicrobial Chemotherapy 17: 309–314, 1986

  8. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by co-administration of colloidal bismuth subcitrate: clinical and in vitro studies. Journal of Clinical Pathology 41: 207–210, 1988

  9. Graham DT. Campylobacter pylori and peptic ulcer disease. Gastroenterology 96: 615–625, 1989

  10. Ho J, Lui I, Hui WM, Ng NMT, Lam JK. A study on the correlation of duodenal ulcer healing with campylobacter-like organisms. Journal of Gastroenterology and Hepatology 1: 69–74, 1986

  11. Lambert JR, Borromeo M, Eaves ET, Hansky J, Korman M. Efficacy of different dosage regimens of bismuth in eradicating Campylobacter pylori. Gastroenterology 95: A248, 1988

  12. Lambert JR, Hansky J, Davidson A. Campylobacter like organisms (CLO) - in vivo and in vitro susceptibility to antimicrobial and antiulcer therapy. Gastroenterology 88: 1462, 1985

  13. Lambert JR, Way DJ, King RG, Wan A, McLean AJ. Bismuth pharmacokinetics in the human gastric mucosa. Gastroenterology 94: A248, 1988

  14. Lee A, Dent J, Haxell S. Origin of spiral organisms in human gastric antrum. Lancet 1: 300–301, 1988

  15. Lee A, Eckstein RP, Ferre DT. Non Campylobacter pylori spiral organisms in the gastric antrum. Australian and New Zealand Journal of Medicine 19: 156–158, 1989

  16. Marshall BJ, Goodwin CS, Warren JR. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2: 1437–1442, 1988

  17. McNulty CAM, Dent JC. Susceptibility of Campylobacter pylori to twenty-one antimicrobial agents. European Journal of Clinical Microbiology and Infectious Diseases 7: 566–569, 1988

  18. Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. Gastroenterology 95: 1178–1184, 1988

  19. Owen RJ, Martin SR, Burman P. Rapid urea hydrolysis by gastric Campylobacters. Lancet 1: 111, 1985

  20. Rauws EAJ, Langenberg W, Houthoff WJ, Zanen HC, Tytgat GNJ. Campylobacter pylori associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and anti-ulcer treatment. Gastroenterology 95: 33–40, 1988

  21. Shirokova KI, Filomonov RM, Poliakova LV. Metronidazole in the treatment of peptic ulcer. Klinicheskaia Meditsina 59: 40–50, 1981

  22. Zheng ZT, Wang ZY, Chu YX. Double-blind short-term trial of furazolidone in peptic ulcer. Lancet 1: 1048–1049, 1985

Download references

Author information

Correspondence to Dr John R. Lambert.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lambert, J.R. Effect of Antiulcer Drugs on Helicobacter pylori . Drug Invest 2, 52–55 (1990). https://doi.org/10.1007/BF03259182

Download citation


  • Bismuth
  • Eradication Rate
  • Tinidazole
  • Nitrofuran
  • Carbenoxolone